Free Trial

Alvotech (ALVO) Competitors

Alvotech logo
$8.63 -0.10 (-1.15%)
Closing price 04:00 PM Eastern
Extended Trading
$8.84 +0.21 (+2.42%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALVO vs. VTRS, QGEN, ASND, BBIO, BPMC, VRNA, ROIV, ELAN, RVMD, and LEGN

Should you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.

Alvotech vs. Its Competitors

Viatris (NASDAQ:VTRS) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Viatris has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.

Alvotech has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viatris$14.74B0.71-$634.20M-$3.17-2.80
Alvotech$491.98M5.29-$231.86M$0.3723.32

Alvotech has a net margin of 16.42% compared to Viatris' net margin of -26.45%. Viatris' return on equity of 16.20% beat Alvotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Viatris-26.45% 16.20% 7.01%
Alvotech 16.42%-36.37%12.70%

Viatris presently has a consensus target price of $10.40, indicating a potential upside of 17.12%. Alvotech has a consensus target price of $16.00, indicating a potential upside of 85.40%. Given Alvotech's stronger consensus rating and higher possible upside, analysts plainly believe Alvotech is more favorable than Viatris.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viatris
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80
Alvotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Viatris had 10 more articles in the media than Alvotech. MarketBeat recorded 15 mentions for Viatris and 5 mentions for Alvotech. Viatris' average media sentiment score of 1.20 beat Alvotech's score of 0.65 indicating that Viatris is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viatris
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
8 Negative mention(s)
0 Very Negative mention(s)
Positive
Alvotech
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

79.9% of Viatris shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 0.5% of Alvotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Alvotech beats Viatris on 10 of the 16 factors compared between the two stocks.

Get Alvotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALVO vs. The Competition

MetricAlvotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.63B$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E Ratio15.058.2821.0120.09
Price / Sales5.29303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book-6.307.678.125.65
Net Income-$231.86M-$55.28M$3.25B$257.91M
7 Day Performance1.29%2.50%0.97%2.09%
1 Month Performance-4.22%11.70%7.36%11.13%
1 Year Performance-27.54%4.89%31.31%18.40%

Alvotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALVO
Alvotech
2.7275 of 5 stars
$8.63
-1.1%
$16.00
+85.4%
-27.1%$2.63B$491.98M15.051,032Analyst Forecast
VTRS
Viatris
3.2683 of 5 stars
$9.20
-1.3%
$10.40
+13.0%
-21.7%$10.94B$14.74B-2.9032,000Trending News
QGEN
Qiagen
3.7474 of 5 stars
$47.49
-1.8%
$49.40
+4.0%
+16.9%$10.75B$1.98B119.075,765Positive News
ASND
Ascendis Pharma A/S
3.6333 of 5 stars
$175.98
+1.0%
$220.67
+25.4%
+27.9%$10.65B$393.54M-28.021,017Positive News
BBIO
BridgeBio Pharma
4.6238 of 5 stars
$43.50
-1.1%
$58.85
+35.3%
+67.0%$8.35B$221.90M-12.32400Analyst Revision
BPMC
Blueprint Medicines
1.0832 of 5 stars
$128.40
+0.0%
$128.25
-0.1%
+13.2%$8.29B$508.82M-51.98640News Coverage
Positive News
VRNA
Verona Pharma PLC American Depositary Share
2.2988 of 5 stars
$91.20
-0.4%
$107.36
+17.7%
+358.8%$7.79B$42.28M-45.6030
ROIV
Roivant Sciences
2.6714 of 5 stars
$10.74
-2.3%
$17.50
+62.9%
+3.6%$7.47B$29.05M-42.96860
ELAN
Elanco Animal Health
1.8068 of 5 stars
$14.48
-1.1%
$15.33
+5.9%
+14.6%$7.27B$4.44B19.579,000Analyst Upgrade
Analyst Revision
RVMD
Revolution Medicines
4.5503 of 5 stars
$36.67
-3.2%
$68.00
+85.4%
-15.9%$7.05B$11.58M-9.17250Analyst Forecast
LEGN
Legend Biotech
3.5835 of 5 stars
$35.87
+0.6%
$72.60
+102.4%
-23.4%$6.55B$627.24M-60.802,609News Coverage
Positive News
Analyst Forecast
Analyst Revision

Related Companies and Tools


This page (NASDAQ:ALVO) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners